Treatment Strategy for Non-Responders to PDE5 Inhibitors
The World Journal of Men's Health
;
: 31-35, 2013.
Artigo
em Inglês
| WPRIM
| ID: wpr-186056
ABSTRACT
Currently, phosphodiesterase type 5 (PDE5) inhibitors are the initial treatment option for erectile dysfunction. The reported efficacy of PDE5 inhibitors is about 70%, although it is significantly lower in difficult-to-treat subpopulations. Treatment failures might be due to the severity of the underlying pathophysiology, improper use of medication, unrealistic patient expectations, difficult relationship dynamics, severe performance anxiety, and other psychological problems. Physicians must address these issues to identify true treatment failures attributable to the drugs. This article discusses factors that might affect the response to PDE5 inhibitors and develops a strategy to maximize the overall efficacy of PDE5 inhibitors in initial non-responders to PDE5 inhibitors.
Texto completo:
DisponíveL
Índice:
WPRIM (Pacífico Ocidental)
Assunto principal:
Piperazinas
/
Purinas
/
Sulfonas
/
Triazinas
/
Carbolinas
/
Falha de Tratamento
/
Inibidores da Fosfodiesterase 5
/
Ansiedade de Desempenho
/
Citrato de Sildenafila
/
Dicloridrato de Vardenafila
Tipo de estudo:
Estudo prognóstico
Limite:
Humanos
/
Masculino
Idioma:
Inglês
Revista:
The World Journal of Men's Health
Ano de publicação:
2013
Tipo de documento:
Artigo
Similares
MEDLINE
...
LILACS
LIS